+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found

      Body Mass Index in Growth Hormone Deficient Children before and during Growth Hormone Treatment

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          Growth hormone deficiency (GHD) is associated with truncal obesity. We aimed at identifying factors that determine the body mass index (BMI) of untreated GHD children and the changes in BMI during 2 years of GH therapy in 348 Dutch GHD children registered in the National GH Registration Database. BMI was expressed as a standard deviation score (SDS). Before GH therapy, the mean (95% CI) BMI-SDS in all GHD children (0.09 (–0.05 to 0.24) SDS) was comparable to normal children. Patients with GHD due to a cranial tumour have a higher BMI (1.03 (0.69–1.36) SDS; p < 0.0001) as well as those with multiple pituitary hormone deficiencies (0.35 (0.14–0.57) SDS; p = 0.005) and patients who are in puberty at start of GH therapy (0.60 (0.13–1.08) SDS; p = 0.036). During GH therapy BMI initially decreased to reach a nadir of –0.28 (–0.35 to –0.21) SDS at 6 months. Thereafter BMI progressively increased to –0.09 (–0.18 to –0.04) SDS after 24 months. A higher initial BMI-SDS resulted in a larger decrease in BMI-SDS. We showed that this can be sufficiently explained by a regression to the mean effect.

          Related collections

          Most cited references 1

          • Record: found
          • Abstract: not found
          • Article: not found

          Factors predicting the response to growth hormone (GH) therapy in prepubertal children with GH deficiency

           S L Blethen (1993)

            Author and article information

            Horm Res Paediatr
            Hormone Research in Paediatrics
            S. Karger AG
            January 1998
            16 December 1997
            : 49
            : 1
            : 39-45
            a Bureau of the Dutch Growth Foundation, Departments of b Paediatrics and c Medical Statistics, Leiden University, Leiden, The Netherlands
            23124 Horm Res 1998;49:39–45
            © 1998 S. Karger AG, Basel

            Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

            Page count
            Figures: 2, Tables: 4, References: 29, Pages: 7
            Original Paper


            Comment on this article